An Exploratory Study of A-337 in the Management of Malignant Solid Dose
Latest Information Update: 28 Oct 2023
At a glance
- Drugs A 337 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ITabMed
- 07 Jun 2023 According to an ITabMed media release, company announced the IND approval from China National Medical Products Administration (NMPA) for A-337.
- 22 Jun 2017 New trial record